Literature DB >> 23908592

Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment.

Javier Freire1, Daniel Ajona, Gabriel de Biurrun, Jackeline Agorreta, Victor Segura, Elizabeth Guruceaga, Anne-Marie Bleau, Ruben Pio, David Blanco, Luis M Montuenga.   

Abstract

The association between inflammation and lung tumor development has been clearly demonstrated. However, little is known concerning the molecular events preceding the development of lung cancer. In this study, we characterize a chemically induced lung cancer mouse model in which lung cancer developed in the presence of silicotic chronic inflammation. Silica-induced lung inflammation increased the incidence and multiplicity of lung cancer in mice treated with N-nitrosodimethylamine, a carcinogen found in tobacco smoke. Histologic and molecular analysis revealed that concomitant chronic inflammation contributed to lung tumorigenesis through induction of preneoplastic changes in lung epithelial cells. In addition, silica-mediated inflammation generated an immunosuppressive microenvironment in which we observed increased expression of programmed cell death protein 1 (PD-1), transforming growth factor-β1, monocyte chemotactic protein 1 (MCP-1), lymphocyte-activation gene 3 (LAG3), and forkhead box P3 (FOXP3), as well as the presence of regulatory T cells. Finally, the K-RAS mutational profile of the tumors changed from Q61R to G12D mutations in the inflammatory milieu. In summary, we describe some of the early molecular changes associated to lung carcinogenesis in a chronic inflammatory microenvironment and provide novel information concerning the mechanisms underlying the formation and the fate of preneoplastic lesions in the silicotic lung.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23908592      PMCID: PMC3730043          DOI: 10.1593/neo.13310

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  51 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk.

Authors:  Jiali Xu; Zhiqiang Yin; Wen Gao; Lingxiang Liu; Rongsheng Wang; Puwen Huang; Yongmei Yin; Ping Liu; Rongbin Yu; Yongqian Shu
Journal:  Clin Lung Cancer       Date:  2011-08-02       Impact factor: 4.785

3.  Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis.

Authors:  Sandra Lo Re; Marylène Lecocq; Francine Uwambayinema; Yousof Yakoub; Monique Delos; Jean-Baptiste Demoulin; Sophie Lucas; Tim Sparwasser; Jean-Christophe Renauld; Dominique Lison; François Huaux
Journal:  Am J Respir Crit Care Med       Date:  2011-08-25       Impact factor: 21.405

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

6.  Ki-ras oncogene mutations in tumors and DNA adducts formed by benz[j]aceanthrylene and benzo[a]pyrene in the lungs of strain A/J mice.

Authors:  M J Mass; A J Jeffers; J A Ross; G Nelson; A J Galati; G D Stoner; S Nesnow
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

7.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Authors:  Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

8.  Cyclopenta[cd]pyrene-induced tumorigenicity, Ki-ras codon 12 mutations and DNA adducts in strain A/J mouse lung.

Authors:  S Nesnow; J A Ross; G Nelson; K Wilson; B C Roop; A J Jeffers; A J Galati; G D Stoner; R Sangaiah; A Gold
Journal:  Carcinogenesis       Date:  1994-04       Impact factor: 4.944

9.  Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice.

Authors:  M E Hegi; P Söderkvist; J F Foley; R Schoonhoven; J A Swenberg; F Kari; R Maronpot; M W Anderson; R W Wiseman
Journal:  Carcinogenesis       Date:  1993-05       Impact factor: 4.944

10.  Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation.

Authors:  Peter Barta; Carolyn Van Pelt; Taoyan Men; Burton F Dickey; Reuben Lotan; Seyed Javad Moghaddam
Journal:  Mol Cancer       Date:  2012-01-12       Impact factor: 27.401

View more
  12 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 2.  Nivolumab in NSCLC: latest evidence and clinical potential.

Authors:  Raghav Sundar; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

3.  Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.

Authors:  Tong-Chun Xue; Qing-An Jia; Ning-Ling Ge; Yi Chen; Bo-Heng Zhang; Sheng-Long Ye
Journal:  Tumour Biol       Date:  2015-06-10

4.  Pharmacological inhibition of caspase-8 limits lung tumour outgrowth.

Authors:  Michela Terlizzi; Vincenzo Giuseppe Di Crescenzo; Giuseppe Perillo; Antonio Galderisi; Aldo Pinto; Rosalinda Sorrentino
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 5.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

6.  Pulmonary Inflammation and KRAS Mutation in Lung Cancer.

Authors:  Phouthone Keohavong; Y Peter Di
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Targeting PD-1/PD-L1 in lung cancer: current perspectives.

Authors:  María González-Cao; Niki Karachaliou; Santiago Viteri; Daniela Morales-Espinosa; Cristina Teixidó; Jesús Sánchez Ruiz; Miquel Ángel Molina-Vila; Mariacarmela Santarpia; Rafael Rosell
Journal:  Lung Cancer (Auckl)       Date:  2015-07-31

Review 8.  Emerging Role of Immunosuppression in Diseases Induced by Micro- and Nano-Particles: Time to Revisit the Exclusive Inflammatory Scenario.

Authors:  François Huaux
Journal:  Front Immunol       Date:  2018-11-19       Impact factor: 7.561

Review 9.  Silicosis and lung cancer: current perspectives.

Authors:  Takashi Sato; Takeshi Shimosato; Dennis M Klinman
Journal:  Lung Cancer (Auckl)       Date:  2018-10-26

10.  Systematic Overview of Solid Particles and Their Host Responses.

Authors:  Fei Shu; Yan Shi
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.